Loading...
XASXSOM
Market cap64mUSD
Jan 06, Last price  
0.48AUD
1D
0.00%
1Q
39.13%
Jan 2017
-87.49%
Name

Somnomed Ltd

Chart & Performance

D1W1MN
XASX:SOM chart
P/E
—
P/S
1.13
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.27%
Rev. gr., 5y
9.25%
Revenues
92m
+9.61%
377,1231,785,9212,273,4683,658,1737,995,47410,992,00012,512,82715,328,82718,488,87130,274,59634,437,90344,084,15349,326,97452,393,58358,892,03357,296,29362,706,35272,580,40383,616,16491,651,069
Net income
-12m
L+53.04%
-3,266,637-4,188,304-3,274,364-2,731,119-1,818,673786,143739,537524,680588,793405,861597,224165,005-3,343,8782,316,781-39,386-1,118,544-1,193,008-4,436,967-7,999,044-12,241,726
CFO
-6m
L+63.21%
-3,433,035-3,747,836-2,335,125-2,115,289-1,317,423461,463172,682289,782572,001-790,409-242,2252,105,023-2,679,670-9,468,837-6,547,1405,189,2762,705,7741,857,690-3,880,204-6,332,766
Earnings
Feb 26, 2025

Profile

SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
URL
https://somnomed.com/en/
IPO date
Aug 27, 2004
Employees
300
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
91,651
9.61%
83,616
15.20%
72,580
15.75%
Cost of revenue
82,009
76,158
66,769
Unusual Expense (Income)
NOPBT
9,642
7,458
5,811
NOPBT Margin
10.52%
8.92%
8.01%
Operating Taxes
971
822
931
Tax Rate
10.07%
11.02%
16.01%
NOPAT
8,671
6,636
4,881
Net income
(12,242)
53.04%
(7,999)
80.28%
(4,437)
271.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
33,929
BB yield
-111.53%
Debt
Debt current
2,603
2,569
6,657
Long-term debt
9,821
25,527
5,353
Deferred revenue
Other long-term liabilities
720
787
4,517
Net debt
(3,755)
16,100
(3,898)
Cash flow
Cash from operating activities
(6,333)
(3,880)
1,858
CAPEX
(1,387)
(6,415)
(8,788)
Cash from investing activities
(5,341)
(6,415)
(8,472)
Cash from financing activities
16,678
6,608
2,092
FCF
8,417
3,022
6,107
Balance
Cash
16,179
11,956
15,644
Long term investments
40
264
Excess cash
11,596
7,816
12,279
Stockholders' equity
45,024
22,403
27,788
Invested Capital
40,868
38,652
27,586
ROIC
21.81%
20.04%
19.35%
ROCE
18.38%
16.05%
14.58%
EV
Common stock shares outstanding
120,717
82,149
82,143
Price
0.25
-73.61%
0.96
-21.07%
1.21
-45.25%
Market cap
30,421
-61.22%
78,452
-21.07%
99,394
-45.16%
EV
26,665
94,552
95,496
EBITDA
16,447
12,575
9,747
EV/EBITDA
1.62
7.52
9.80
Interest
3,167
2,627
380
Interest/NOPBT
32.84%
35.22%
6.54%